Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study

Revista Brasileira de Psiquiatria

Volumn 35, Issue 4, 2013, Pages 432-434

  Ortiz, Bruno Bertolucci ^a,b   Filho Araújo, Gerardo Maria de ^a,c   Araripe Neto, Ary Gadelha de Alencar ^a   Medeiros, Daiane ^b   Bressan, Rodrigo Affonseca ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Luzia de Pinho Melo   (Brazil)

^c São Josádo Rio Preto Medical School   (Brazil)

Author keywords

Clinical predictors; Clozapine response; Disorganized schizophrenia; Subtypes of schizophrenia; Treatment resistant schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; FEMALE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; SYMPTOM; THERAPY RESISTANCE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA, DISORGANIZED; SCHIZOPHRENIA, PARANOID; YOUNG ADULT;

EID: 84891524180     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2013-1190     Document Type: Article

References (14)

1. American Psychiatric Association. Highlights of changes from DSMIV-TR to DSM-5 [Internet]. 2013. Available from: http://www. psych. uic. edu/docassist/changes-from-dsm-iv-tr--to-dsm-51. pdf.
2. Taylor MA, Shorter E, Vaidya NA, Fink M. The failure of the schizophrenia concept and the argument for its replacement by hebephrenia: applying the medical model for disease recognition. Acta Psychiatr Scand. 2010; 122: 173-83.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-DSM-IV-TRH. 4th ed. Arlington: American Psychiatric Publishing; 2000.
4. Cuesta MJ, Peralta V, De Leon J. Schizophrenic syndromes associated with treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 1994; 18: 87-99.
5. Fenton W, McGlashan TH. Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry. 1991; 48: 969-77.
6. Braff DL, Ryan J, Rissling AJ, Carpenter WT. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull. 2013; 39: 751-3.
7. Suvisaari J, Perälä J, Saarni SI, Juvonen H, Tuulio-Henrikson A, Lönnqvist J. The epidemiology and descriptive and predictive validity of DSM-IV delusional disorder and subtypes of schizophrenia. Clin Schizophr Relat Psychoses. 2009; 2: 289-97.
8. Hill M, Freudenreich O. Clozapine: key discussion points for prescribers. Clin Schizophr Relat Psychoses. 2013; 6: 177-85.
9. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009; 7-14.
10. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006; 163: 743-5.
11. Uçok A, Polat A, Genç A, Cakiotar S, Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res. 2004; 38: 163-8.
12. Joffe G, Venälä inen E, Tulapa J, Hiltunen O, Wahlbeck K, Gädeke R, et al. The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in out-patients. Int Clin Psychopharmacol. 1996; 11: 265-72.
13. Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol. 2012; 22: 818-24.
14. Rodriguez VM, Catalina ML, Garcia-Noblejas JA, Cuesta P. Schizophrenic syndromes and clozapine response in treatmentresistant schizophrenia. Psychiatry Res. 1998; 77: 21-8.